Precipio, Inc. · NASDAQ:PRPO
Precipio — Investor Presentation (August 2025)
12 slides from Precipio's investor presentation, August 2025
Slide 1: Diagnostics Biotech Company
Diagnostics Biotech Company NASDAQ: PRPO Founded in 2011 HQ: New Haven, CT DI S C L AI M E R T HIS PRESENT AT ION HAS BEE N PREPARE D B Y P RE CIPIO IN C. (T HE “C O MPAN Y”) AND IS GENERA L BA CKGROUND IN FOR MAT I ON ABOUT T HE C O MPAN Y’S ACT IV IT IES AS O F T HE DAT E O F T HIS PRESENT AT ION
Slide 2: We develop products that save lives
We develop products that save lives Acute Myeloid Leukemia (AML) is one of the deadliest forms of cancer. Physicians treating patients with AML face two unsuitable options. Precipio’s assay enables immediate, targeted treatment - SAVING LIVES Patient diagnosed with AML Molecular tests ordered (10-15
Slide 3: Precipio is eliminating ineffective diagnosis
Precipio is eliminating ineffective diagnosis We eliminate both misdiagnosis and diagnostic delays, where outcomes depend on speed and accuracy. 25-40%* 10+ $100B** days generally accepted of blood cancer diagnoses diagnostic errors cost US industry turnaround times in are incorrect healthcare annua
Slide 4: We've built an innovative product development platform, creating an unfair advantage
We’ve built an innovative product development platform, creating an unfair advantage Pathology Diagnostics Service Lab Product Division Our Unfair Advantage Facilities, equipment Unsolved diagnostic & talent problems drive innovative We are the first customer of products every product we develop Pat
Slide 5: Our profitable clinical lab business fully funds R&D, significantly de-risking the company
Our profitable clinical lab business fully funds R&D, significantly de-risking the company Example: Clinical Lab Precipio’s ▪ Identifies market needs Product BCR-ABL1 ▪ Provides infrastructure Release assay and patient samples R&D Platform 1. Most advanced assay in market ▪ Leverages infrastructure
Slide 6: We deliver testing options not available before
We deliver testing options not available before Our products address the key challenges laboratories face: Staff shortage, Capital budgets, and the ability to deliver timely results Factor Competition Precipio Solution Impact Simplified workflow enables streamlined Workflow Complex Simple process, f
Slide 7: We scale through national distribution partner agreements already in place
We scale through national distribution partner agreements already in place Go-to-market efficiency through leading channel partners, with nationwide reach Hospital / Reference POL* Academic Lab * Physician-Owned Laboratory 7
Slide 8: Blood cancers are just the beginning: Expanding into a $40B+ market
Blood cancers are just the beginning: Expanding into a $40B+ market Our technology is platform-ready to expand beyond hematology into broader cancer and molecular testing. PRESENT: NEAR TERM: LONG TERM: Blood Cancer Genetics Cancer Genetics Molecular Diagnostics 2.5% blood TAM: $500M* TAM $6.7B** TA
Slide 9: Recurring revenue growth, high-margin outlook
Recurring revenue growth, high-margin outlook As we scale products and alter the revenue mix, gross margins increase dramatically. Path Services Revenue mix Products Gross Margin Analysis Products Path services Blended 100% 100% 80% 80% 60% 60% 40% 40% 20% 20% 0% 0% Current Short term Long term Curr
Slide 10: Proven leadership with deep clinical and commercial experience
Proven leadership with deep clinical and commercial experience Ilan Danieli CEO Dr. Ayman Mohamed CTO Zaki Sabet COO Ilan Danieli Dr. Ayman Mohamed Zaki Sabet CEO CTO COO Stephen Miller CCO Matt Gage CFO Miri Radomski CPO Legal Counsel Stephen Miller Miri Radomski Matt Gage CCO CPO & Legal CFO Couns
Slide 11: Precipio: A high-margin, proprietary diagnostics platform with massive upside
Precipio: A high-margin, proprietary diagnostics platform with massive upside Disruptive, Proprietary Products Rooted in solutions to 1 real-world diagnostic and monitoring challenges Unique Development Platform - rapid and 2 capital efficient Massive Market Opportunity – growing from 3 $0.5B TAM to
Slide 12: Thank you.
20250817 Thank you. Please contact us at [email protected]